Transatlantique Private Wealth LLC Sells 26,175 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Transatlantique Private Wealth LLC cut its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 18.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 118,436 shares of the company's stock after selling 26,175 shares during the quarter. PROCEPT BioRobotics accounts for about 3.6% of Transatlantique Private Wealth LLC's investment portfolio, making the stock its 3rd largest holding. Transatlantique Private Wealth LLC owned 0.23% of PROCEPT BioRobotics worth $9,536,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC grew its stake in PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Vanguard Group Inc. increased its holdings in PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after buying an additional 297,075 shares during the last quarter. Alliancebernstein L.P. raised its position in PROCEPT BioRobotics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock valued at $141,110,000 after acquiring an additional 218,148 shares in the last quarter. Wellington Management Group LLP raised its position in PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock valued at $120,051,000 after acquiring an additional 416,819 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in PROCEPT BioRobotics by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock valued at $93,751,000 after acquiring an additional 57,449 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ PRCT traded down $0.84 during mid-day trading on Friday, hitting $51.72. The company had a trading volume of 1,392,394 shares, compared to its average volume of 805,778. The business's 50-day simple moving average is $58.33 and its 200-day simple moving average is $74.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81. The firm has a market cap of $2.84 billion, a P/E ratio of -26.60 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Waters sold 733 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PRCT has been the topic of a number of recent research reports. Truist Financial cut their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Bank of America reduced their price target on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Friday. Finally, Morgan Stanley lowered their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $90.00.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).